The NMDA receptor (NMDA-R) has pivotal roles in neural development, learning, memory and synaptic plasticity. Functional impairment of NMDA-R has been implicated in schizophrenia. NMDA-R activation requires glycine to act on the GlyB site of the NMDA-R as an obligatory co-agonist with glutamate. Extracellular glycine near NMDA-R is regulated effectively by a glial glycine transporter 
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INTRODUCTION:
Functional heteromeric NMDA receptors (NMDA-R), consisting of an obligatory combination of a NR1 subunit with any of the four NR2 (A-D) subunits (Monyer et al., 1992; 1994; Cull-Candy et al 2001) , are critically involved in neural development, synaptic plasticity, excitotoxicity, learning and memory (Bliss and Collingridge, 1993; Malenka and Nichol, 1999) . The ionotropic NMDA-R possess multiple modulation sites on the receptor subunits: voltage-dependent Mg 2+ block of the receptor channel pore (Nowak et al., 1984; Mayer et al, 1984) , a strychnine-insensitive glycine-B (GlyB) site on the NR1 subunit, a phencyclidine (PCP) site on NR2 subunit; as well as the Zn 2+ , polyamine, glycosylation and polyamine sites (McBain and Mayer 1994) . Extracellular glycine is an obligatory coagonist for NMDA receptor activation (Johnson and Asher, 1987; Kleckner and Dingledine, 1988; Thomson, 1990; Parsons et al. 1998) . Only when glycine binds to the GlyB site on the NR1 subunit, with glutamate to the glutamate binding site on NR2 subunits, do single NMDA-R channels open (Hirai et al., 1996; Currás and Pallotta 1996; Laube et al 1997; Anson et al 1998) . Functionally, this glycine binding allosterically influence NMDA receptor to increase the recovery rate from receptor desensitization during synaptic activation (Mayer et al., 1989; Vyklicky et al., 1990; Benveniste et al., 1990; Lester et al 1993) .
A considerable debate centers on whether the GlyB site on the NMDA-R is saturated under physiological condition in vivo. Early in vitro studies suggested that endogenous glycine could have saturated the GlyB site on the NMDA receptor (Fletcher and Lodge, 1988; Kemp et al 1988; Bashir et al., 1990) . Indeed, extracellular glycine concentration ([glycine] o) is in the micromolar range in vivo, and that the measured affinity of the GlyB site for glycine on NMDA receptor is in the sub-micromolar range (Ki = 0.1 -0.3 µM) (Grimwood et al 1992; Baron et al 1996) . However, recent findings suggest that [glycine] O near the NMDA-R in the forebrain is efficiently regulated by a Na + /Cl --dependent, astroglial, high capacity glycine transporter (GlyT) adjacent to the NMDA-R (Smith et al 1992; Borowsky et al 1993; Zafra et al., 1995) . Hence, the transport actions of GlyT1 and / or intracellular glycine sequestration may exceed the Kd of the glycine binding site and help to rapidly keep [glycine] o near the NMDA-R to low levels (e.g. < 1 µM; Supplisson and Bergman 1997; Bergeron et al., 1998) .
GlyTs belong to a superfamily of 12 trans-membrane domains, Na + -dependent, neurotransmitter transporters. Two different genes, GlyT1 and GlyT2, encode GlyT. Transcription of GlyT1 gene resulted in at least 3 mRNA isoforms: GlyT1a, GlyT1b, GlyT1c, and with transcription of GlyT1a and GlyT1b mediated by alternative promoter usage (Kim et al., 1994; Borowsky and Hoffman, 1998; Adam et al. 1995) . While GlyT2 mRNAs are present in axonal terminals of glycinergic neurons and
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4 specifically regulate strychnine-sensitive glycinergic neurotransmission in brainstem and spinal cord, GlyT1 mRNAs are heterogeneously present in frontal cortex and hippocampus, as well as lower brainstem and spinal cord (Zafra et al 1997; Borowsky et al 1993; Legendre, 2001; Smith et al., 1992) .
GlyT1 can remove glycine efficiently near the NMDA-R, as well as releasing glycine upon changes in extracellular glycine and / or ionic composition (Fedele and Foster, 1992; Herdon et al., 2001; Sakata et al., 1997; Supplisson and Bergman, 1997; Berger et al., 1998) . Saturation of the GlyB site by glycine in vivo may depend on the density of GlyT1, as well as the regional differences of local brain glycine levels (see Danyz and Parsons, 1998; Wood, 1995) .
Dysfunction of the prefrontal cortex (PFC) and of central NMDA-R plays a crucial role in the complex pathophysiology including severe cognitive deficits in schizophrenia (Weinberger and Berman, 1996; Goldman-Rakic, 1999; Breier 1999; Yang et al., 1999; Tamminga, 1998; Tsai and Coyle, 2002; Javitt and Zukin, 1991) . One therapeutic strategy is to administer daily a large glycine dose (e.g. in grams per day, due to its poor CNS penetrance, Oldendorf, 1973), or GlyB site agonist D-serine, or a partial agonist cycloserine. These treatment approaches led to reported improvement of neuropsychiatric symptoms, presumably via potentiation of NMDA-R functions (Javitt et al 1994; Heresco-Levy and Javitt. 1999; Tsai et al 1998; 1999; Goff et al., 1999) .
Another way to elevate endogenous [glycine] O near NMDA-R is to block glycine uptake by GlyT1, although the question on whether GlyB site is saturated in PFC in vivo must first be clarified.
The sarcosine derivative N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS, also known as ALX-5407) represents a useful tool that has been shown to block glycine uptake by glial GlyT1 (Ki = 5 nM; IC50 = 0.03 -0.22 µM; Bergeron et al., 1998; Aubrey and Vandenberg, 2001; Herdon et al., 2001; Atkinson et al., 2001) and to augment hippocampal NMDA-R-mediated synaptic responses in vitro (Bergeron et al.,1998 Preliminary results have been reported in an abstract form (Chen et al, 2001 ).
5 MATERIALS AND METHODS
Brain Slice Preparations
The experiments were performed in brain slices prepared from young adult (P25-35) male 
Whole-Cell Patch-Clamp Recordings
An upright Olympus BX50WI microscope equipped with differential interference contrast optics and infrared videoimaging system (DIC-IR, Hamamatsu C2400-07ER) was used to visualize neurons in slices. Layer V-VI PFC pyramidal neurons were easily recognizable via a 40X water-immersion lens by the pyramidal shape of their cell bodies and the presence of a long apical dendrite extending towards superficial layers. In some neurons, the morphology of single neurons from which recordings were made using biocytin (0.2%)-filled patch pipettes was confirmed by streptavadin-horseradish peroxidase staining of biocytin (Yang et al., 1996) . 'break-in') was not compensated but was monitored periodically during the entire experiment.
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Recordings were terminated and the data are discarded if the series resistance changed by > 10M .
In the voltage-clamp experiments, the slices were initially bathed with continuously oxygenated (95% O 2 , 5% CO 2 ) ACSF containing (in mM): NaCl (124), NaHCO 3 (26) the competitive NMDA antagonist APV (50 µM) was added to ensure that all inward currents evoked and potentiated were NMDA receptor mediated (see Fig. 1 & 3B ).
Synaptic Stimulations
Electrical stimulation was delivered via a concentric bipolar metal stimulating electrode (MCE- Conventional extracellular single-unit recordings with iontophoresis were made using five-barrel glass micropipettes. The multi-barrel pipette blanks (World Precision Instruments, U.S.A.) were pulled by a vertical Narishige pipette puller (PE-2, Narishige Inc, Japan). The recording center barrel was filled with 0.5% sodium acetate in 2% Pontamine Sky blue mixed with bicuculline methiode (0.5 µM)
was mixed into the pipette solution and the slow leak of bicuculline is used to partially block local GABA A receptor mediated tonic inhibitory responses (Gigg et al., 1994) . The side-barrels were filled with NMDA (0.2 mM, pH 8; Sigma, U.S.A.), the Gly-B site antagonist (+)HA-966 (0.2 mM, pH 4); and NaCl (200 mM, for current balancing). The electrode was advanced by a single-axis hydraulic micromanipulator (MHW-40-1 Narishige Inc., Tokyo, Japan) mounted onto the stereotaxic frame.
Extracellular single-unit activity was amplified by a Xcell-3 Plus amplifier (Frederick Haer Co., Brunswick, U.S.A.). Amplified (gain: 100,000X ; lowpass filter at 5 kHz, highpass filter at 500Hz) single unit activity was isolated using a window discriminator (Model 74-60-3, Frederick Haer Co.).
The output signals from the window discriminator were digitized and multiplexed by an A/D converter (1401 mini, Cambridge Electronics Design Ltd., CED, U.K.) and were sampled at 10 kHz by a PCbased computer using Spike 2 software (Version 4, Cambridge Electronics Design Ltd., CED, U.K.).
Programmed NMDA pulses (-20 to -40 nA) were iontophoretically applied repeatedly (Dagan 6400 , Dagan Corp., U.S.A.) for 10 -20 secs every 45 -60 secs to evoke firing of single PFC neurons.
(+)HA-966 was iontophoretically applied (30 to 80 nA) continuously to block the NMDA-evoked firing
responses. An additional barrel in the 5-barrel pipette contains saline (0.9% NaCl). Automatic ejection of currents in opposite polarity with respect to drug ejection current applied was made for current balancing to eliminate possible current artifacts.
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8 To verify the position of the microelectrode, DC current (10 µA, for 15 min) was delivered to iontophorese Pontamine Sky blue through the recording electrode to mark the recording site. The animal then was perfused transcardially with saline, followed by buffered formalin. Brain sections (70 µm) containing the PFC were cut using a freezing microtome (Leitz, Germany) and the sections were washed, dehydrated with alcohol and stained with cresyl violet to permit examination of the recording sites.
Drug Applications
For in vitro brain slice experiments, all drugs used were bath-applied by gravity. Stock solutions of DL-2-Amino-5-phosphonovaleric acid (APV), bicuculline, 5,7 dichlorokyneurinc (5,7-DCK),
(+)HA-966, and D-serine were prepared in de-ionized water. All other drugs including the selective
sarcosine (NFPS) were dissolved in dimethyl-sulfoxide (DMSO), and stored as frozen aliquots at -20 o C and diluted to appropriate concentrations in ACSF for slice perfustion.
For in vivo experiments, NFPS was first dissolved in 200 µl of ethanol. An appropriate amount of a hydroxy-beta cyclodextran solution (50%, HBC; Sigma, U.S.A.) was added and sonicated briefly.
Deionized water was then added to make a final concentration of HBC to 15%. Intravenous administration of drug vehicle alone showed no change in iontophoretic NMDA-evoked firing.
Data Analyses
For in vitro brain slice experiments, the integrated areas and amplitudes of evoked EPSCs were measured using pClamp 8.0 software (Axon Instruments, USA). The decay time constant of the averaged NMDA EPSC was fitted for two exponentials from the peak of the EPSC to the end of the trace using standard exponential fitting formula in pClamp 8.0 (Axon Instruments, U.S.A.).
i is the current as a function of time (t), and Ai and τi are the amplitude and time constant of each component of the current, respectively. C is constant y-offset for each component i. The NMDA-EPSC 9 trace recorded following different doses of GlyT inhibitor NFPS, glycine or D-serine was scaled to the same peak amplitude of the pre-drug control EPSC. All group data were presented as mean ± S.E.M.
ANOVA and post-hoc Dunnett's test was used to compare differences between group mean data with control group mean. Differences between control and experimental responses with p<0.05 were deemed significant. Student's 't'-test was used for group comparison to determine exogenous glycine and D-serine effects on evoked NMDA EPSCs.
For in vivo iontophoretic data, the control NMDA-evoked firing measured from 5 to 6 repeated stable baseline responses were averaged and analyzed using Spike 2 software (version 4, C.E.D, Cambridge, U.K.). Following systemic drug injections, the mean firing rates evoked by NMDA application that consist of responses at 20% or greater than baseline NMDA-evoked responses were taken for comparison with the baseline mean dataGroup data comparisons were made using one-way ANOVA, followed by post-hoc Dunnet's test (GraphPad Prism Software).
[ Figure 1 near here]
RESULTS:
In Vitro Experiments
Characterization of synaptically evoked NMDA-EPSC.
Electrical stimulation of layer V-VI synaptically evoked a mixed EPSC in layer V-VI pyramidal neurons. The EPSC was dominated by a large, fast AMPA receptor component. Bath application of the drug cocktail containing AMPA and GABA B antagonists in low [Mg 2+ ] o superfusate, resulted in a gradual blockade over time of the prominent AMPA EPSC. This was followed by a slow emergence of the NMDA EPSC, which was pharmacologically confirmed by its sensitivity to blockade with the competitive NMDA antagonist APV (50 µM, n = 3), or the GlyB site NMDA antagonist 5,7 dichlorokynurenate (5,7-DCK) (50 µM, n = 3) (Fig 1) . This suggests that the evoked EPSC is NMDA receptor mediated. (10 µM) potentiated the NMDA EPSC integrated areas (Fig. 1B) . The increase in evoked NMDA
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10 EPSC began at approximately -75 mV and gradually, the evoked inward current increased with more positive holding potentials to a maximal current evoked at -50 mV. There was a voltage-dependent reduction of the evoked NMDA EPSC with holding potentials more positive than -50 mV (Fig 1B) . 1994; Lester et al 1990; Gibb and Colquhoun 1991) , intrinsic properties of the combined NMDA receptor subunits (Monyer et al., 1994; Vinci et al., 1998; Cull-Candy et al., 2001) , and Ca 2+ mediated receptor desensitization (Tong et al., 1995; McBain and Mayer, 1994; Lerma et al., 1990; Clark et al 1990; Zilberter et al 1991) . The decay time-constant (tau, τ) of the NMDA-EPSC in PFC neurons could be fitted by two exponentials (D'Angelo et al., 1990; 1994) : a fast, and a slow component, typically found in > P22 day old rats as used in this study. The mean decay time of the slow τ reduces with age and this may be due to an age-dependent switch of the NMDA receptor subunit from NR2B to NR2A (Hestrin, 1992; Carmignoto and Vicini, 1992; Flint et al 1997; Kew et al., 1998) . Fig. 2A, 2B ). Group data summarized in Fig 2C show One action of glycine is to accelerate the recovery of NMDA receptors from desensitization (Mayer et al., 1989; Lerma et al., 1990; Vyklicky et al., 1993; Benveniste et al., 1990) . As a result, glycine lengthens the duration of the decay time constants (τ) (Fig 2B, upper) of the evoked NMDA EPSCs. However, we found that glycine at 1, 10 and 100 µM exerted an inverted-'U' dose response profile for the NMDA EPSC in PFC slices (Fig. 2D, right The GlyB site agonist D-serine (Brugger et al., 1990 ) potentiated the peak amplitude and τ Slow of the NMDA-EPSCs in individual neurons (Fig 2B) , thus yielding a net dose-dependent increase in the integrated area (Fig. 2C) . In some individual PFC neurons, although D-serine showed a dosedependent trend in enhancing τ Slow of the NMDA EPSC (Fig. 2D ), ANOVA test [F(3,21)=0.8; p =0.5] applied to group data failed to show a statistical dose dependent change in the τ Slow of the NMDA EPSC (p> 0.05; Fig 2E) . Like glycine, D-serine at 1, 10, 100 µM also did not change the τ Fast of the evoked NMDA-EPSC (Fig 2E) .
[ Figure 3 near here]
GlyT1 inhibitor potentiates synaptically evoked NMDA current in PFC neurons in vitro
In the absence of added extracellular glycine (≤ 100 nM glycine present in the solution), NMDAEPSCs were also evoked by electrical stimulation of the local afferents. This suggests that trace amount of glycine is likely to be present in the tissue and/or the perfusate (as trace contaminant or metabolic product). When the GlyT1 inhibitor NFPS was bath-applied (0.01 µM), it moderately potentiated the evoked NMDA EPSC ( 15%). However, further increases in the concentration of NFPS (from 0.1 to 10 µM) failed to cause further increases in the evoked NMDA EPSCs, suggesting
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12 that the effects of glycine on NMDA EPSC was at its maximum when there was no added extracellular glycine present in the media.
Since extracellular glycine levels in the PFC in vivo are approximately 10 µM (Hashimoto and Oka, 1997), we included 10 µM glycine in our low Mg 2+ perfusate in the experiments to determine the effects of GlyT inhibitor NFPS on evoked NMDA EPSCs. Application of NFPS (from 0.01 -10µM) dose-dependently augmented the integrated area of the evoked NMDA-EPSCs (Fig. 3B, C) . Group data analysis of the decay τ of the NMDA EPSC shows that like glycine and D-serine, NFPS did not change the mean fast decay τ of the NMDA EPSC. Group analyses of the slow decay τ show that NFPS up to 1 µM showed a trend in causing a dose-dependent lengthening of the NMDA EPSC [F(4, 31)=3.43, p < 0.01]. Only at 1 µM did NFPS show a statistically significant increase of the slow decay τ with respect to the control (Dunnet's test, p < 0.01). Increasing the NFPS concentration to 10µM (with 10µM glycine) had no effect on the slow decay τ of the NMDA EPSC.
[ Figure 4 near here]
To rule out the possibility that NFPS might potentiate the NMDA EPSC via other mechanisms, we have conducted an additional experiment. In the presence of a saturating concentration of GlyB site agonist D-serine (100 µM) that is not normally transported by GlyT1 (Broer et al 1990; Supplisson and Bergman, 1997; Schell et al., 1995; Snyder and Kim, 2000; Snyder and Ferris, 2000; Ribeiro et al., 2002) , the fully potentiated NMDA EPSC could not be further changed by the GlyT1 inhibitor NFPS (in 10 µM glycine) (Fig. 3E ). This result suggests that NFPS did not have any additional unanticipated properties on NMDA EPSC.
It is difficult to absolutely rule out an increase in NMDA 
Effects of D-serine and NFPS on iontophoretic NMDA-evoked excitatory responses in PFC neurons in vivo
Systemic injection of the GlyT inhibitor NFPS (1 -2 mg/kg,i.v.) significantly enhanced the NMDA-evoked spike firing (+76 ± 10%; p<0.05, n = 6 ; Fig 4 A-D) in single PFC neurons in vivo (Fig 4) .
Since NFPS does not interact with NMDA-R (e.g. NFPS does not displace MDL105519 or MK-801 binding of the glycine, or the channel pore sites, respectively, of the NMDA receptor, Bergeron et al 1998; David Calligaro, personal communication), the most plausible explanation would be that NFPS blocked the GlyT1 to enable sufficient glycine accumulate near NMDA-R to potentiate the NMDAevoked firing. This finding may further support the suggestion that the GlyB site of the NMDA-R is not saturated in PFC.
[ Figure 5 near here] D-serine is moderately better than glycine in penetrating the blood-brain-barrier when administered systemically (Oldendorf, 1973) . In our in vivo studies, we tested whether the GlyB site of the NMDA receptor in the PFC was saturated by using the GlyB site agonist D-serine to probe this issue. Iontophoretically application of NMDA (-20 to -60 nA) , at an inter-application interval of ~ 1min reliably excited single PFC neurons. Following acquiring a stable baseline of the NMDA-evoked firing responses, we administered D-serine (50 -100 mg / kg, i.v.) (Fig. 5A) . Over a short period of time (10 -15 min), the same NMDA iontophoretic pulses now elicited a significantly greater (+ 89.77 ± 8.75 %; p < 0.05) number of spikes in these same neurons (n = 6). Since glycine and D-serine interact at the same GlyB site on the NMDA receptor, the enhancement of NMDA-evoked firing response by Dserine suggests that the GlyB site on the NMDA receptor, like that in visual cortex and hippocampus (Salt, 1989; Dalkara et al., 1992; Mizutani et al 1991; Czepita et al., 1996) is not saturated by endogenous glycine in rat PFC in vivo (Fig. 4, 5 ).
D-serine or GlyT1 inihibitor reverses the blockade of GlyB site of NMDA receptor by (+)HA-966 in PFC neurons in vivo.
To further determine how elevation of extracellular glycine may enable endogenous glycine to interact with the GlyB site of the NMDA receptor to potentiate NMDA-evoked spike firing, we continuously applied iontophoretically a selective GlyB antagonist (+)HA-966 (Foster and Kemp, 1989) 10/17/2002 14 to block the NMDA evoked firing response first. We then administered the D-serine to compete with HA-966 at the GlyB sites of the NMDA receptor, or GlyT1 inhibitor NFPS to block GlyT1, which result in an elevation of extracellular PFC glycine levels in vivo (Atkinson et al., 2001 ).
[ Figure 6 near here]
In separate series of experiments using continuous iontophoretic application of ( In nominal absence of extracellular glycine (HPLC analysis of ACSF showed < 100 nM glycine present), NMDA EPSC can clearly be synaptically evoked and pharmacologically isolated in our study.
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15 Endogenous GlyB site NMDA agonists such as D-serine might be present in the slices and acted as a coagonist. Since D-serine is not taken up by GlyT1 (Schell et al., 1995; Snyder and Kim, 2000; Snyder and Ferris, 2000; Ribeiro et al., 2002; Broer et al 1990) At high doses of glycine (100 µM) or NFPS (10 µM; in the presence of 10µM glycine), the NMDA EPSC peak was potentiated, but the slow decay time constant did not differ from the control. One possibility is that the enhanced NMDA EPSC will increase enough Ca 2+ influx via NMDA-R to activate calcineurin to cause a glycine-insensitive NMDA-R desensitization (Legendre et al., 1993; Tong et al., 1995; Rosenmund et al., 1995) . Thus, at higher concentration of extracellular glycine, the secondary events (i.e. onset of Ca 2+ -mediated NMDA-R desensitization) can prevent this glycine prolongation of the late τ Slow while the high glycine continued to increase early NMDA receptor channel openings (see Table 1 in Parsons et al., 1993) .
[ Figure 7 near here]
The issue regarding saturation of the high affinity GlyB (Ki = 0.1-0.3 µM) site of the NMDA-R in vivo has been controversial (see Introduction). Although microdialysis studies in freely moving animals have shown that the extracellular concentration of glycine in the rat PFC may be as high as ~10 µM (Hashimoto et al., 1995) , glycine levels at the GlyB site of the NMDA-R at the synapse may be much less than 1µM due to the efficient glycine uptake by the GlyT1 (Supplisson and Bergman 1997) .
Our in vivo electrophysiological recordings showed that by blocking the GlyT1 using NFPS, NMDA- Although it is used as an exogenous GlyB site agonist in this study, endogenous D-serine is also synthesized in glia cells and is highly concentrated in forebrain areas enriched in NMDA-R (Schell et al., 1995; . D-serine is not a substrate for the GlyT1, but is transported by the ASCT2 system of transporters (Ribeiro et al., 2002; Broer et al 1990) . Synaptically released glutamate may activate ionotropic glutamate receptors on astroglia to release D-serine. In turn, the released endogenous Dserine can serve to co-activate NMDA-R on adjacent postsynaptic neurons (Snyder and Kim. 2000; Baranano et al., 2001 ). However, during repeated iontophoretic NMDA application to establish a stable baseline prior to any systemic drug injections, we did not observe a gradual increase in NMDAevoked firing over time. Hence, it is unlikely that the ionotophoretic application of exogenous NMDA stimulated glia D-serine release in vivo.
Hypofunction of the glutamate/NMDA receptor system has been implicated in the pathophysiology of schizophrenia (Javitt and Zurkin, 1991; Tsai and Coyle, 2002) . The clinical finding that GlyB site stimulation following administration of a large quantity of exogenous glycine (because of its poor CNS penetration) or D-serine as an adjunct to atypical antipsychotics improves schizophrenic symptoms, support the hypothesis that hypo-NMDA system is likely to be involved in the complex pathophysiology of schizophrenia (Javitt et al., 1994; Tsai et al., 1998) . The current finding that blocking the GlyT1 may augment endogenous glycine to a level sufficient to potentiate NMDA-R function in vivo may provide a good rationale to implement this kind of strategy for treating schizophrenia. Perhaps the more important question remaining is to determine to what extent that potentiation of NMDA-R function is beneficial, and to address possible excitotoxicity. Animal studies show a lack of neurotoxic damage following long-term pharmacological glycine exposure (Patel et al., 1990; Shoham et al., 1999) and that other glycine transporter inhibitors reverse behavioral
17 hyperactivity caused by psychotomimetic NMDA receptor blockader ketamine .
These findings further provide a compelling rationale for using GlyT1 inhibitors to indirectly potentiate NMDA receptor functions safely in schizophrenia.
10/17/2002 condition. In the graphical plot the peak NMDA EPSC responses were observed at a Vm -50 mV and displays a region of negative slope conductance. We chose a holding potential of -75 to -80 mV for evoking our control NMDA EPSC in this study. Left: GlyT1 is located on the glial compartment adjacent to a glutamatergic synapse. Under physiological condition, glycine is actively tranported into the glial cell by a Na + /Cl -dependent GlyT1.
Postsynaptic glutamate activation of NMDA-R requires co-activation by extracellular glycine for NMDA-R channel opening.
